Home — Pipeline
PipelineA diverse, de-risked biologics pipeline.
From biosimilars to advanced platforms — Theertha is building a broad portfolio of recombinant proteins, peptides, antibodies, industrial enzymes and next-generation delivery technologies, developed on scalable, technology-led processes.
Eleven programmes across metabolic, haematology and ophthalmology targets.
Development stages shown reflect current programme status and are indicative of technical progress; they do not imply regulatory approval, clinical status or commercial availability.
High-value biocatalysts, clone-to-product ready.
A portfolio of recombinant enzymes developed on Theertha's microbial expression and purification platforms, with clone and process development complete.
Enterokinase (EK)
Highly specific protease for the cleavage of fusion tags in recombinant protein production.
Taq Polymerase (PRJ003)
Thermostable DNA polymerase for routine PCR amplification.
RNase Inhibitor (PRJ005)
Protects RNA from ribonuclease degradation across molecular-biology workflows.
Reverse Transcriptase (PRJ002)
RNA-dependent DNA polymerase for first-strand cDNA synthesis.
Pfu Polymerase (PRJ007)
High-fidelity, proofreading DNA polymerase for accurate amplification.
Technology platforms for advanced modalities.
Plasmid isolation platform for gene therapy
An integrated fermentation and purification platform for plasmid DNA, supporting gene-therapy and advanced-modality programmes at development scale.
Liposomal encapsulation platform for mRNA
A lipid-nanoparticle encapsulation platform under development for mRNA and other advanced delivery applications.
Explore a programme or platform with us.
Whether you are seeking a biosimilar development partner, a recombinant enzyme supply, or access to our plasmid and liposomal platforms — let's talk.